OR7-10 | Outcomes of Transcatheter Aortic Valve Replacement In Patients With Amyloidosis: A Comparative Meta-Analysis

Amyloidosis is a prevalent comorbidity seen in those with aortic valve abnormalities. While transcatheter aortic valve replacement (TAVR) has become increasingly performed, outcomes of TAVR in those with coexisting amyloidosis remain not fully understood. We aimed to evaluate outcomes among patients with amyloidosis versus those without amyloidosis undergoing TAVR. We searched several databases for studies comparing outcomes of TAVR in patients with amyloidosis to those without amyloidosis. We applied the generic inverse variance statistical method after extracting the odds ratios (OR) with the corresponding 95% confidence intervals (CI) to the pooled OR of each outcome in R studio. Outcomes assessed were acute kidney injury, all-cause mortality, arrhythmias, major bleeding, pacemaker insertion, and stroke. A total of 3 studies were identified. There were significantly increased odds of stroke in those with amyloidosis undergoing TAVR compared to those without amyloidosis (OR 1.97; 95% CI 1.05 - 3.69). Odds of acute kidney injury (OR 1.19; 95% CI .81 - 1.75), all-cause mortality (OR 1.14; 95% CI 0.77 - 1.69), arrhythmias (OR 1.28; 95% CI .88 - 1.86), major bleeding (OR .75; 95% CI .48 - 1.18) and pacemaker implantation (OR 0.63; 95% CI .36 - 1.09) were similar between both groups. This meta-analysis found patients with amyloidosis undergoing TAVR had increased odds of stroke, with otherwise similar odds of adverse events, compared to those without amyloidosis. These findings may serve as a framework for procedural considerations in amyloidosis patients requiring aortic valve interventions.